The active ingredient of this product is fluoxetine hydrobromide.


This product is a light yellow circular film coated tablet, which appears white or off white after removing the coating.
This product is used to treat adult depression.
Calculated as C18H22N2S (1) 5mg (2) 10mg
This product should be taken orally and can be taken with food or on an empty stomach.
The initial dose and recommended dose of this product are both 10mg once daily. According to individual patient reactions, the dosage can be increased to a maximum of 20mg once daily, or reduced to a minimum of 5mg once daily.
After the relief of depressive symptoms, it is recommended to continue receiving treatment with this product for at least 6 months to consolidate the antidepressant effect.
Patients receiving treatment with this product do not need to gradually reduce their dosage when discontinuing the medication.
No need to adjust dosage based on kidney or liver function
Patients who are allergic to the active ingredients or any excipients of this product are prohibited from using it.
Prohibition of combination with non selective monoamine oxidase inhibitors (MAOIs) or selective monoamine oxidase A (MAO-A) inhibitors
In clinical studies, taking this product at a dose range of 40mg-75mg can cause the following adverse reactions to worsen: nausea, positional dizziness, diarrhea, abdominal discomfort, generalized itching, drowsiness, and flushing.
The post market experience of this product mainly includes drug overdose, up to 80mg. In most cases, there are no relevant symptom reports or symptoms are only mild. The most commonly reported symptoms are nausea and vomiting.
The experience of using this product above 80mg is limited. When the dosage of medication is several times higher than the therapeutic dose, seizures and serotonin syndrome may occur.
The disposal methods for drug overdose include symptomatic treatment and relevant monitoring, and it is recommended to undergo medical follow-up.
Sealed storage at no more than 30 ℃. Please keep this product out of reach of children.
https://www.cisenpharmagroup.com/